Lungpacer Medical, Inc. Presents Preclinical Results at American Association for Respiratory Care Congress, November 2019, New Orleans, Louisiana
Findings from ongoing preclinical research using Lungpacer’s novel phrenic nerve pacing technology was presented at the American Association for Respiratory Care Congress 2019. The preclinical study investigated aspects of lung dynamics in non-injured porcine lungs during 50 hours of mechanical ventilation: Synchronous Diaphragm Contraction via Temporary Transvenous Diaphragm Neurostimulation During Mechanical Ventilation Decreases Peak Inspiratory […]
RESCUE 1 Study Findings Presented at American Thoracic Society Conference, May 2019, Dallas, Texas
VANCOUVER, British Columbia, May 2019 Lungpacer Medical, Inc. announced that two abstracts were presented by colleagues at the University of Florida, Shands Hospital from the RESCUE 1 early feasibility study. The study uses a novel device containing a transvenous phrenic nerve stimulating catheter (LIVE Catheter®) to stimulate the diaphragm in ventilated patients and determine the […]
Lungpacer Medical, Inc. Presents at WSGR 2018 Medical Device Conference, June 2018, San Francisco, California
Doug Evans, CEO of Lungpacer Medical, Inc., presented at the Wilson Sonsini Goodrich & Rosati 2018 Medical Conference in San Francisco, CA. The WSGR Conference consists of a series of topical panels presented over the course of one day. Attendees heard from CEOs of innovative MedTech Companies, venture capitalists, industry strategists, investment bankers, and market […]
ATSJournals Publication – Mitigation of Ventilator-Induced Diaphragm Atrophy by Transvenous Phrenic Nerve
The top-ranked American Journal of Respiratory and Critical Care Medicine has published on-line a pre-clinical research study demonstrating that the Lungpacer therapy mitigated ventilator-induced diaphragm atrophy in pigs that were sedated and ventilated in ICU-like conditions for 60 hours.
Lungpacer Medical, Inc. Presents Preclinical Data at American Thoracic Society Conference, May 2018, San Francisco, California
This multidisciplinary conference attracts pulmonary and critical care clinicians from around the world. Liz Rohrs presented her preclinical work, which concluded that ventilation in four paced animals showed a greater posterior distribution of ventilation during paced breaths than four control animals (p < 0.001). PaO2/FiO2 ratios significantly worsened (p = 0.04) over 50 hours of […]
Lungpacer Medical, Inc. Presents at Respiratory Innovation Summit, May 2018, San Francisco, California
Lungpacer Medical Inc. was invited to present at the inaugural RIS meeting in San Francisco, CA. The Respiratory Innovation Summit unites the innovators, investors and clinicians who are leading the fight to create powerful new treatments for deadly and crippling diseases of the lungs and airways. Lungpacer CEO, Doug Evans, presented preclinical research utilizing Lungpacer’s […]
Lungpacer Medical, Inc. Announces Completion of RESCUE 1 Feasibility Study
BURNABY, British Columbia, January 2018 Lungpacer Medical, Inc., announced the completion of enrollment into the RESCUE 1 feasibility study. This novel, first-of-its-kind, FDA-designated breakthrough device delivered temporary transvenous diaphragmatic neurostimulation (TTDN) in a small cohort of patients suffering from failure to wean from MV. All patients were considered to have VIDD at the time of […]
Lungpacer Medical, Inc. Announces the Opening of US Headquarters
BURNABY, British Columbia, January 2018 Lungpacer Medical, Inc. has opened its US headquarters in Exton, PA, with the corporate headquarters remaining in Vancouver, British Columbia. Product development and manufacturing for the Company’s respiratory stimulation devices will be conducted at the Exton facility.
Lungpacer Medical, Inc. Announces Enrollment of First Subject in RESCUE 2 European Clinical Study
BURNABY, British Columbia, 29 September 2017 Lungpacer Medical, Inc., announced today that the first subject has been enrolled in the RESCUE 2 European CE Mark clinical study of its proprietary phrenic-nerve pacing system. This is a randomized study being conducted in France and Germany, to evaluate the safety and effectiveness of the Lungpacer Therapy System […]
Lungpacer Medical, Inc. Announces Publication of First-In-Human (FIH) Study Results in Critical Care Medicine
BURNABY, British Columbia, July 2017 Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today that the FIH study results of the PACER study have been published in the journal Critical Care Medicine. This First-in-Human case series demonstrates that the diaphragm can contribute significantly to the work of breathing when […]
